Treated Cord Blood Stem Cell Transplants Appear Safe

Umbilical cord blood units treated with a signaling molecule has shown a favorable safety profile in long-term animal studies, report scientists.

Analysis of long-term safety testing in nonhuman primates, published online by the journal Cell Stem Cell, revealed that, after one year following transplant, umbilical cord blood units treated with a signaling molecule called 16,16-dimethyl PGE2 reconstituted all the normal types of blood cells, and none of the animals receiving treated cord blood units developed cancer. Wolfram Goessling, MD, PhD, of Dana-Farber and Brigham and Women's Hospital, is the first author of the paper, and Trista North, PhD, of BIDMC is the senior author.

The results of long-term safety studies in mice were previously submitted to the Food and Drug Administration to gain permission for a Phase 1 clinical trial under an Investigational New Drug (IND) application. Principal investigator, Corey Cutler, MD, a Dana-Farber transplant specialist, initiated the trial in 2009 at Dana-Farber and the Massachusetts General Hospital. The IND is sponsored by Fate Therapeutics, Inc. of San Diego.

Goessling and North were post-doctoral fellows in the laboratory of co-author Leonard Zon, MD, a stem cell researcher at CHB and a scientific founder of Fate Therapeutics, when they hit upon 16,16-dimethyl PGE2 while looking for compounds that could regulate the production of hematopoietic stem cells. The initial testing made use of zebra fish models. Goessling commented that "this is the first time a compound discovered in zebra fish has received a nod from the FDA for a clinical trial."

One of the limitations of cord blood as a transplant source is the cells engraft, or "take," in the recipient's bone marrow more slowly than matched donor cells form bone marrow. In addition, there is a higher failure rate for cord blood transplants. Thus there is a need for ways to improve the speed and quality of cord blood transplantation.

Source: Eurekalert

Stem Cells - Cord Blood

Encyclopedia section of medindia gives general info about Cord Blood

Stem Cells - Fundamentals

Encyclopedia section of medindia gives general info about Stem Cells

Study Examines Usefulness of Umbilical Cord Blood-Derived Stem Cells for Lupus Therapy

Recent research has indicated that human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have been found to offer benefits for treating lupus nephritis

Diabetic Wound Healing A Lot Faster Using Human Umbilical Cord Blood Cells

Korean scientists have found that transplanting human umbilical cord blood-derived endothelial progenitor cells (EPCs) 'significantly accelerate' wound closure in diabetic mouse models.

Blood in Stools - Symptom Evaluation

Blood in stools results from bleeding that arises from any part of the digestive tract. Causes of blood in stools are hemorrhoids, diverticulosis, colorectal cancer, gastric cancer.

Bombay Blood Group

Bombay blood group is a rare blood type in which the people have an H antigen deficiency. They can receive or donate blood only with other individuals with the same blood group.

Graft versus Host Disease (GvHD)

Graft versus host disease (GvHD) occurs when donor cells recognize the host cells as foreign and begin to attack it. Symptoms can be mild, severe or even fatal.